Sebastián Rivera-Orellana

Sebastián Rivera-Orellana

Auto-generated profile, based on publicly available information

Sebastián Rivera-Orellana

Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SRSebastián Rivera-Orellana
Sebastián Rivera-Orellana
JYJustin Yeager
Justin Yeager
ETEduardo Tejera
Eduardo Tejera
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
Growing antimicrobial resistance (AMR) infections are among the top contemporary concerns in public healthcare systems which can place considerable burdens on healthcare systems. Phage therapy has long been considered a viable option to help combat AMR infections, including on broad geographic scales. One bottleneck in the application of phage therapy is the accurate matching of host-specific phages to bacterial strains, which is traditionally done using molecular techniques. Here we present an open-access deep learning-based model that shows incredible potential to accurately predict phages for therapeutic use. Our goal is to attenuate the matching process so that specific phages, or a cocktail of phages can be prepared for patients with a high probability of therapeutic success, helping to democratize phage therapy treatments even in low to middle-income countries where genomic resources can be limited, costly, or time prohibitive. We feel this is an important first step towards incorporating and applying bioinformatic practices in promising fields such as phage therapy.

6 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SRSebastián Rivera-Orellana
Sebastián Rivera-Orellana
JRJosé Rubén Ramírez-Iglesias
José Rubén Ramírez-Iglesias
JAJaime David Acosta-España
Jaime David Acosta-España
JEJorge Patricio Espinosa-Espinosa
Jorge Patricio Espinosa-Espinosa
JNJuan-Carlos Navarro
Juan-Carlos Navarro
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
The Mpox virus (Monkeypox virus) poses significant public health risks due to its potential for severe outbreaks in humans. This study presents an innovative vaccine design using bioinformatics to identify epitopes that activate helper T cells (HTLs) via the human leukocyte antigen class II (HLA-II) complex. Starting with 50,040 vaccine candidates, 14 epitopes with the highest HLA-II affinity were selected based on antigenicity, allergenicity, toxicity, stability, and homology. These epitopes were integrated into a multi-epitope vaccine with spacers and adjuvants to enhance the immune response. A 3D model was developed, confirming structural stability and optimal epitope exposure through molecular dynamics simulations. The results indicate that the vaccine can induce robust immune responses, suggesting its potential effectiveness against the Mpox virus. Additionally, population coverage analysis supports its promise as a significant tool for controlling Mpox epidemics and advancing global public health initiatives.